JPWO2022256449A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022256449A5
JPWO2022256449A5 JP2023574118A JP2023574118A JPWO2022256449A5 JP WO2022256449 A5 JPWO2022256449 A5 JP WO2022256449A5 JP 2023574118 A JP2023574118 A JP 2023574118A JP 2023574118 A JP2023574118 A JP 2023574118A JP WO2022256449 A5 JPWO2022256449 A5 JP WO2022256449A5
Authority
JP
Japan
Prior art keywords
claudin
cancer
polypeptide
tac
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522357A (ja
JP2024522357A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031836 external-priority patent/WO2022256449A1/en
Publication of JP2024522357A publication Critical patent/JP2024522357A/ja
Publication of JP2024522357A5 publication Critical patent/JP2024522357A5/ja
Publication of JPWO2022256449A5 publication Critical patent/JPWO2022256449A5/ja
Pending legal-status Critical Current

Links

JP2023574118A 2021-06-01 2022-06-01 クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 Pending JP2024522357A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163202211P 2021-06-01 2021-06-01
US63/202,211 2021-06-01
US202163263809P 2021-11-09 2021-11-09
US63/263,809 2021-11-09
US202263362594P 2022-04-06 2022-04-06
US63/362,594 2022-04-06
PCT/US2022/031836 WO2022256449A1 (en) 2021-06-01 2022-06-01 Claudin 18.2 t cell-antigen couplers and uses thereof

Publications (3)

Publication Number Publication Date
JP2024522357A JP2024522357A (ja) 2024-06-18
JP2024522357A5 JP2024522357A5 (https=) 2025-06-10
JPWO2022256449A5 true JPWO2022256449A5 (https=) 2025-06-10

Family

ID=84324567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574118A Pending JP2024522357A (ja) 2021-06-01 2022-06-01 クローディン１８．２ｔ細胞－抗原カプラーおよびその使用

Country Status (7)

Country Link
US (2) US12016923B2 (https=)
EP (1) EP4347660A4 (https=)
JP (1) JP2024522357A (https=)
KR (1) KR20240037892A (https=)
AU (1) AU2022283819A1 (https=)
CA (1) CA3173810A1 (https=)
WO (1) WO2022256449A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
JP2026503268A (ja) * 2023-01-06 2026-01-28 トリウムビラ イミュノロジクス ユーエスエー，インク． ヒト化ｇｕｃｙ２ｃ ｔ細胞抗原カプラーおよびその使用
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724320B1 (fr) 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
DK0912738T3 (da) 1996-05-22 2008-11-17 Viventia Biotech Inc Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
UA75049C2 (uk) 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
JP2003111595A (ja) 2001-06-25 2003-04-15 Kyogo Ito 腫瘍抗原
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
KR101335798B1 (ko) 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
ES2538990T3 (es) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
JP5426531B2 (ja) 2007-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
US8460647B2 (en) 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
NZ591087A (en) 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
JP5985481B2 (ja) 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
WO2012118622A1 (en) 2011-02-19 2012-09-07 Baylor Research Institute Diagnostic and therapeutic uses for b cell maturation antigen
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
JP2015510877A (ja) 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
JP2016531100A (ja) 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
JP2016539929A (ja) 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
AU2017305524B2 (en) 2016-08-04 2024-09-26 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN108250302A (zh) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
CN112074600A (zh) * 2018-05-03 2020-12-11 科济生物医药（上海）有限公司 免疫效应细胞及其应用
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
AU2019307905B2 (en) 2018-07-17 2024-09-12 Mcmaster University T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US20220127372A1 (en) 2019-02-01 2022-04-28 Cafa Therapeutics Limited Tcr fusion protein and cell expressing tcr fusion protein
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2022256449A5 (https=)
Wu et al. Building blocks for bispecific and trispecific antibodies
AU2018385756B2 (en) CD19 variants
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
JP2019536430A5 (https=)
JP2020500523A5 (https=)
JP2020525032A5 (https=)
JP2021522162A5 (https=)
JP2021530236A5 (https=)
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
Khan et al. Targeting the HIV-1 spike and coreceptor with bi-and trispecific antibodies for single-component broad inhibition of entry
JP2021501567A5 (https=)
JPWO2020059847A5 (https=)
Liguori et al. Bispecific antibodies: A novel approach for the treatment of solid tumors
Fabozzi et al. Bispecific antibodies: Potential immunotherapies for HIV treatment
WO2021129891A1 (zh) 可结合cd4的多肽及其应用
CN108276492A (zh) 抗pd－l1单克隆抗体及其应用
CN116964099A (zh) 针对NKp46的抗体及其应用
JP6876006B2 (ja) 癌免疫療法に使用するための二重特異性抗体
JP7645824B2 (ja) 抗－ｃｄ１２３抗体、抗－ｃｄ１２３キメラ抗原受容体および抗－ｃｄ１２３キメラ抗原受容体ｔ細胞
KR20230025655A (ko) 암 치료용 조성물 및 방법
JPWO2022068854A5 (https=)
Cabanillas-Bernal et al. Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2
JPWO2022109010A5 (https=)
JPWO2022183101A5 (https=)